Search company, investor...


Founded Year




Total Raised


Date of IPO


About NGeneBio

NGeneBio is a molecular diagnostics (MDx) and companion diagnostics (CDx) company that develops and provides next-generation sequencing (NGS)-based in vitro diagnostics (IVD) panel and clinical analysis software (SW).

Headquarters Location

Dareong Post Tower 1st, Rooms 304-306 288, Digital-ro, Guro-gu

Seoul, 08390,

South Korea

+82 2 867 9798

Missing: NGeneBio's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: NGeneBio's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing NGeneBio

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

NGeneBio is included in 4 Expert Collections, including Medical Devices.


Medical Devices

8,633 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.



1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data


Health Monitoring & Diagnostics

76 items

Companies developing companion diagnostics and technology enabling the development of companion diagnostics. Tagged as #CompanionDx


Health IT

7,901 items

NGeneBio Patents

NGeneBio has filed 5 patents.

The 3 most popular patent topics include:

  • Health informatics
  • Bacteriology
  • Dietary supplements
patents chart

Application Date

Grant Date


Related Topics



Molecular biology, Genetics, Experimental cancer drugs, Transcription factors, Breast cancer


Application Date


Grant Date


Related Topics

Molecular biology, Genetics, Experimental cancer drugs, Transcription factors, Breast cancer



Latest NGeneBio News

LabGenomics, NGeneBio joint forces for US market

Dec 2, 2022

LabGenomics, NGeneBio joint forces for US market NGeneBio supplies NGS diagnostic products to LabGenomics By NGeneBio and LabGenomics signed an MOU to move into the US market (Yonhap) Korea's two diagnostics companies, NGeneBio and LabGenomics, signed a memorandum of understanding (MOU) on Thursday to cooperate in the field of next-generation sequencing (NGS) services. The two companies will work together in developing NGS-based services both in the domestic and the US market. For this, they intend to take advantage of a US Clinical Laboratory Improvement Amendments (CLIA) Lab, which LabGenomics plans to acquire.  After taking over a CLIA, LabGenomics, together with NGeneBio, plans to develop LDT services that applied their advanced diagnostic technologies to CLIA Lab's diagnostic process. NGeneBio will supply LabGenomics with NGS diagnostics products, bioinformatics software, and laboratory-developed test (LDT) services. It will export NGS products to the US once LabGenomics completes the acquisition of the CLIA Lab. Meanwhile, the biggest shareholder LabGeneomics signed in September a contract to sell its managerial rights to Luha Private Equity, South Korea, at 90 billion won. Capitalizing on 94.1 billion won in cashable assets, Luha plans to promote genetic testing molecular diagnosis services and new overseas business. Write to In-Hyuk Park at

NGeneBio Frequently Asked Questions (FAQ)

  • When was NGeneBio founded?

    NGeneBio was founded in 2015.

  • Where is NGeneBio's headquarters?

    NGeneBio's headquarters is located at Dareong Post Tower 1st, Rooms 304-306, Seoul.

  • What is NGeneBio's latest funding round?

    NGeneBio's latest funding round is IPO.

  • How much did NGeneBio raise?

    NGeneBio raised a total of $23.17M.

  • Who are the investors of NGeneBio?

    Investors of NGeneBio include Korea Technology Finance Corporation, Ildong Pharmaceutical, P&I Investment, K-Run Ventures, DSC Investment and 10 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.